Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1321853

GTEX

c2d77403-bbb2-5e9f-8b29-94702263315b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.474
  • CHOLESTEROL_HOMEOSTASIS+0.396
  • INFLAMMATORY_RESPONSE+0.384
  • INTERFERON_GAMMA_RESPONSE+0.370
  • BILE_ACID_METABOLISM+0.369
  • FATTY_ACID_METABOLISM+0.361
  • IL2_STAT5_SIGNALING+0.344
  • INTERFERON_ALPHA_RESPONSE+0.342
  • KRAS_SIGNALING_UP+0.334
  • COMPLEMENT+0.330

Top 10 suppressed

  • HEDGEHOG_SIGNALING-0.437
  • WNT_BETA_CATENIN_SIGNALING-0.373
  • MYC_TARGETS_V2-0.292
  • NOTCH_SIGNALING-0.221
  • G2M_CHECKPOINT-0.195
  • MITOTIC_SPINDLE-0.162
  • E2F_TARGETS-0.161
  • UNFOLDED_PROTEIN_RESPONSE-0.084
  • UV_RESPONSE_DN-0.082
  • DNA_REPAIR-0.076

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR660661
brain-umap@2
GTEX—0.927
220110132.TNBC
breast-umap@18
—F0.873
3SRR6013535
lung-landscapes@6
—cohortMD20.871
4SRR1446828
brain-umap@2
GTEX—0.869
5SRR4195658
colon-landscapes@1
——0.864
6BS_HV8PFRBR
brain-umap@2
pilocytic astrocytoma—0.864
7SRR1488538
brain-umap@2
GTEX—0.862
8AUR-AFR2-TTP1-A-1-1-R-A742-41
breast-umap@18
—C0.862
9SRR603397
brain-umap@2
GTEX—0.859
10BS_T0RKFEKR
brain-umap@2
pilocytic astrocytoma—0.859

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.474Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.396Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.384Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.370Idelalisib— uncovered
BILE_ACID_METABOLISM0.369Inavolisib— uncovered
FATTY_ACID_METABOLISM0.361Inavolisib— uncovered
IL2_STAT5_SIGNALING0.344Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.342Inavolisib— uncovered
KRAS_SIGNALING_UP0.334Inavolisib— uncovered
COMPLEMENT0.330Inavolisib— uncovered
PROTEIN_SECRETION0.322Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.309Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.309Inavolisib— uncovered
APOPTOSIS0.301Idelalisib— uncovered
ANDROGEN_RESPONSE0.286Inavolisib— uncovered
COAGULATION0.284Binimetinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.281Remibrutinib— uncovered
ADIPOGENESIS0.278Inavolisib— uncovered
MYC_TARGETS_V10.273Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.263Inavolisib— uncovered